NASDAQ:VYNE VYNE Therapeutics (VYNE) Stock Forecast, Price & News $5.63 -0.32 (-5.38%) (As of 06/8/2023 ET) Add Compare Share Share Today's Range$5.61▼$5.9950-Day Range$2.58▼$8.6652-Week Range$1.99▼$9.90Volume8,639 shsAverage Volume458,558 shsMarket Capitalization$18.41 millionP/E RatioN/ADividend YieldN/APrice Target$18.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media VYNE Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside228.6% Upside$18.50 Price TargetShort InterestHealthy2.93% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$74,600 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($5.61) to ($2.11) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.10 out of 5 starsMedical Sector406th out of 986 stocksPharmaceutical Preparations Industry182nd out of 473 stocks 3.3 Analyst's Opinion Consensus RatingVYNE Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $18.50, VYNE Therapeutics has a forecasted upside of 228.6% from its current price of $5.63.Amount of Analyst CoverageVYNE Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.93% of the float of VYNE Therapeutics has been sold short.Short Interest Ratio / Days to CoverVYNE Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in VYNE Therapeutics has recently decreased by 55.56%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldVYNE Therapeutics does not currently pay a dividend.Dividend GrowthVYNE Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VYNE. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for VYNE Therapeutics this week, compared to 1 article on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, VYNE Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $74,600.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 4.00% of the stock of VYNE Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 14.23% of the stock of VYNE Therapeutics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for VYNE Therapeutics are expected to grow in the coming year, from ($5.61) to ($2.11) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of VYNE Therapeutics is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of VYNE Therapeutics is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVYNE Therapeutics has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About VYNE Therapeutics (NASDAQ:VYNE) StockVYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. It develops and commercialize solutions using its proprietary Molecule Stabilizing Technology. Its commercial products include AMZEEQ and ZILXI. The company was founded on October 21, and is headquartered in Bridgewater, NJ.Read More Receive VYNE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VYNE Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address VYNE Stock News HeadlinesJune 6, 2023 | fool.comVYNE Therapeutics (NASDAQ: VYNE)May 28, 2023 | americanbankingnews.comVYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest UpdateJune 8, 2023 | UNKNOWN (Ad)This NASDAQ Stock Is The Amazon Of Medical SupplyThis Little Known Company IS Quickly Becoming The Amazon Of Medical Supply. Learn More NowMay 18, 2023 | finance.yahoo.comVYNE Therapeutics to Attend BIO International ConventionMay 17, 2023 | msn.comCan VYNE Therapeutics Inc. (VYNE) Climb 415.04% to Reach the Level Wall Street Analysts Expect?May 13, 2023 | msn.comCantor Fitzgerald Maintains VYNE Therapeutics (VYNE) Overweight RecommendationMay 13, 2023 | americanbankingnews.comCantor Fitzgerald Increases VYNE Therapeutics (NASDAQ:VYNE) Price Target to $9.00May 12, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM) and VYNE Therapeutics (VYNE)June 8, 2023 | UNKNOWN (Ad)This NASDAQ Stock Is The Amazon Of Medical SupplyThis Little Known Company IS Quickly Becoming The Amazon Of Medical Supply. Learn More NowMay 12, 2023 | finanznachrichten.deVYNE Therapeutics Inc.: VYNE Therapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdateMay 11, 2023 | msn.comRecap: VYNE Therapeutics Q1 EarningsMay 11, 2023 | finance.yahoo.comVYNE Therapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdateMay 11, 2023 | americanbankingnews.comVYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Up 119.1% in AprilMay 6, 2023 | finance.yahoo.comWe Think VYNE Therapeutics (NASDAQ:VYNE) Needs To Drive Business Growth CarefullyMay 1, 2023 | seekingalpha.comVYNE Therapeutics selects lead candidate for immuno-inflammatory treatment programMay 1, 2023 | finance.yahoo.comVYNE Therapeutics Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory ConditionsApril 22, 2023 | americanbankingnews.comHC Wainwright Reaffirms "Buy" Rating for VYNE Therapeutics (NASDAQ:VYNE)April 20, 2023 | msn.comVYNE Gains on Preclinical Data for IPF CandidateApril 19, 2023 | msn.comHC Wainwright & Co. Reiterates VYNE Therapeutics (VYNE) Buy RecommendationApril 19, 2023 | markets.businessinsider.comLifeSci Capital Reaffirms Their Hold Rating on VYNE Therapeutics (VYNE)April 19, 2023 | msn.comWhy Are VYNE Therapeutics Shares Trading Higher Today?April 19, 2023 | msn.comVyne stock jumps as VYN201 shows promise in mice model for lung diseaseApril 19, 2023 | finance.yahoo.comVYNE Therapeutics Announces Positive Preclinical Data for Inhaled Formulation of VYN201 in an In Vivo Model of Idiopathic Pulmonary FibrosisApril 3, 2023 | americanbankingnews.comHC Wainwright Reiterates Buy Rating for VYNE Therapeutics (NASDAQ:VYNE)March 30, 2023 | msn.comVYNE Therapeutics Touts Encouraging Pharmacokinetic, Hematology Data From Potential Candidate For Skin DisorderMarch 30, 2023 | finance.yahoo.comVYNE Therapeutics Announces Positive First-In-Human Pharmacokinetic and Hematology Data from Phase 1a Single and Multiple Ascending Dose Trial for Novel Pan-Bromodomain BET Inhibitor VYN201March 30, 2023 | americanbankingnews.comVYNE Therapeutics Inc. (NASDAQ:VYNE) Sees Large Growth in Short InterestSee More Headlines VYNE Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VYNE Company Calendar Last Earnings5/11/2023Today6/08/2023Next Earnings (Estimated)8/11/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VYNE CUSIPN/A CIK1566044 Webvynetherapeutics.com Phone(800) 755-7936FaxN/AEmployees28Year FoundedN/APrice Target and Rating Average Stock Price Forecast$18.50 High Stock Price Forecast$28.00 Low Stock Price Forecast$9.00 Forecasted Upside/Downside+228.6%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($10.6455) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,210,000.00 Net Margins-8,417.59% Pretax Margin-7,751.26% Return on Equity-84.52% Return on Assets-69.31% Debt Debt-to-Equity RatioN/A Current Ratio4.39 Quick Ratio4.39 Sales & Book Value Annual Sales$480,000.00 Price / Sales38.35 Cash FlowN/A Price / Cash FlowN/A Book Value$9.67 per share Price / Book0.58Miscellaneous Outstanding Shares3,270,000Free Float3,140,000Market Cap$18.41 million OptionableNot Optionable Beta1.60 Key ExecutivesDavid DomzalskiPresident, Chief Executive Officer & DirectorTyler ZerondaChief Financial Officer & TreasurerIain A. StuartChief Scientific OfficerMutya HarschSecretary, Chief Legal Officer & General CounselKey CompetitorsForward Pharma A/SNASDAQ:FWPAYRenovoRxNASDAQ:RNXTTonix PharmaceuticalsNASDAQ:TNXPBionomicsNASDAQ:BNOXChemomab TherapeuticsNASDAQ:CMMBView All CompetitorsInsiders & InstitutionsGeode Capital Management LLCSold 424,140 shares on 5/16/2023Ownership: 0.764%Susquehanna International Group LLPBought 1,528 shares on 5/16/2023Ownership: 0.551%State Street CorpSold 198,381 shares on 5/16/2023Ownership: 0.357%DSC Advisors L.P.Sold 1,455,000 shares on 5/15/2023Ownership: 3.523%HRT Financial LPBought 10,304 shares on 5/12/2023Ownership: 0.316%View All Insider TransactionsView All Institutional Transactions VYNE Stock - Frequently Asked Questions Should I buy or sell VYNE Therapeutics stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VYNE Therapeutics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" VYNE shares. View VYNE analyst ratings or view top-rated stocks. What is VYNE Therapeutics' stock price forecast for 2023? 2 analysts have issued 12-month price targets for VYNE Therapeutics' stock. Their VYNE share price forecasts range from $9.00 to $28.00. On average, they expect the company's share price to reach $18.50 in the next twelve months. This suggests a possible upside of 228.6% from the stock's current price. View analysts price targets for VYNE or view top-rated stocks among Wall Street analysts. How have VYNE shares performed in 2023? VYNE Therapeutics' stock was trading at $2.70 at the beginning of 2023. Since then, VYNE shares have increased by 108.5% and is now trading at $5.63. View the best growth stocks for 2023 here. Are investors shorting VYNE Therapeutics? VYNE Therapeutics saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 91,900 shares, a decrease of 55.6% from the April 30th total of 206,800 shares. Based on an average daily volume of 702,800 shares, the short-interest ratio is presently 0.1 days. Approximately 2.9% of the company's shares are short sold. View VYNE Therapeutics' Short Interest. When is VYNE Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 11th 2023. View our VYNE earnings forecast. How were VYNE Therapeutics' earnings last quarter? VYNE Therapeutics Inc. (NASDAQ:VYNE) posted its earnings results on Thursday, May, 11th. The company reported ($1.74) earnings per share for the quarter, topping analysts' consensus estimates of ($2.50) by $0.76. The company earned $0.10 million during the quarter. VYNE Therapeutics had a negative net margin of 8,417.59% and a negative trailing twelve-month return on equity of 84.52%. When did VYNE Therapeutics' stock split? Shares of VYNE Therapeutics reverse split on the morning of Monday, February 13th 2023. The 1-18 reverse split was announced on Monday, February 13th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, February 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. What other stocks do shareholders of VYNE Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other VYNE Therapeutics investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Novan (NOVN), Organigram (OGI), Zosano Pharma (ZSAN), KushCo (KSHB), Bionano Genomics (BNGO), Pennsylvania Real Estate Investment Trust (PEI), Sorrento Therapeutics (SRNE) and Aeterna Zentaris (AEZS). What is VYNE Therapeutics' stock symbol? VYNE Therapeutics trades on the NASDAQ under the ticker symbol "VYNE." Who are VYNE Therapeutics' major shareholders? VYNE Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include DSC Advisors L.P. (3.52%), BlackRock Inc. (1.50%), Renaissance Technologies LLC (0.78%), Geode Capital Management LLC (0.76%), Staley Capital Advisers Inc. (0.72%) and Susquehanna International Group LLP (0.55%). Insiders that own company stock include Andrew Saik, David Domzalski, Mutya Harsch, Patrick G Lepore and Perceptive Advisors Llc. View institutional ownership trends. How do I buy shares of VYNE Therapeutics? Shares of VYNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is VYNE Therapeutics' stock price today? One share of VYNE stock can currently be purchased for approximately $5.63. How much money does VYNE Therapeutics make? VYNE Therapeutics (NASDAQ:VYNE) has a market capitalization of $18.41 million and generates $480,000.00 in revenue each year. The company earns $-23,210,000.00 in net income (profit) each year or ($10.6455) on an earnings per share basis. How can I contact VYNE Therapeutics? VYNE Therapeutics' mailing address is 520 U.S. HIGHWAY 22 SUITE 204, BRIDGEWATER NJ, 08807. The official website for the company is vynetherapeutics.com. The company can be reached via phone at (800) 755-7936 or via email at jallaire@lifesciadvisors.com. This page (NASDAQ:VYNE) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VYNE Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.